Contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media?

Clinical Radiology

Volumn 64, Issue 5, 2009, Pages 468-472

  Morcos, S K ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IOBITRIDOL; IODINATED CONTRAST MEDIUM; IODINE; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOXAGLIC ACID;

CHRONIC KIDNEY FAILURE; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; HUMAN; HYDRATION; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION; MULTIDETECTOR COMPUTED TOMOGRAPHY; OSMOLARITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

CONTRAST MEDIA; HUMANS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; IODINE ISOTOPES; KIDNEY DISEASES; OSMOLAR CONCENTRATION; RISK FACTORS;

EID: 63449094310     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2008.08.019     Document Type: Review

References (24)

1. Thomsen H.S., and Morcos S.K. Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines. Eur Radiol 16 (2006) 1835-1840
2. Thomsen H.S., and Morcos S.K. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 76 (2003) 513-518
3. Mehran R., and Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int 69 (2006) S11-S15
4. Morcos S.K. Prevention of contrast media nephrotoxicity following angiographic procedures. J Vasc Interv Radiol 16 (2005) 13-23
5. Thomsen H.S., Morcos S.K., and Barrett B.J. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 49 (2008) 646-657
6. Rudnick M.R., Goldfarb S., Wexler L., et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomised trial. Kidney Int 47 (1995) 254-261
7. Taliercio C.P., Vlietstra R.E., Ilstrup D.M., et al. A randomised comparison of nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 17 (1991) 384-390
8. Barrett B., and Carlisle E.J. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188 (1998) 171-178
9. Sharma S., and Kini A. Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. Catheter Cardiovasc Interv 65 (2005) 386-393
10. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 68 (2005) 2256-2263
11. Solomon R., and DuMouchel W. Contrast media and nephropathy. Findings from systematic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol 41 (2006) 651-660
12. Chalmers N., and Jackson R.W. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 72 (1999) 701-703
13. Aspelin P., Aubry P., Fransson S.G., et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348 (2003) 491-499
14. Jo S.-H., Youn T.-J., Koo B.-K., et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabric (ioxaglate) in patients with renal insufficiency undergoing coronary angiography. The RECOVER study: a randomized, controlled trial. J Am Coll Cardiol 48 (2006) 924-930
15. Solomon R.J., Natarajan M.K., Doucet S., et al., The Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) Study. Randomized, double-blind trial of contrast-induced nephropathy in with chronic kidney disease. Circulation 115 (2007) 3189-3196
16. Ni J., Ruiyan Z., Jainsheng Z., et al. Safety of iso-osmolar nonionic dimer during percutaneous coronary intervention. [in Chinese]. J Interv Radiol 15 (2006) 327-329
17. Briguori C., Colombo A., Airoldi F., et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 68 (2005) 2250-2255
18. McCullough P.A., Bertrand M.E., Brinker J.A., et al. A meta-analysis of the renal safety of isosmolar Visipaque compared with low-osmolar contrast media. J Am Coll Cardiol 48 (2006) 692-699
19. Barrett B.J., Katzberg R.W., Thomsen H.S., et al. Contrast induced nephropathy in patients with chronic kidney disease undergoing computed tomography. A double blind comparison of Visipaque and Iopamidol. Invest Radiol 41 (2006) 815-821
20. Thomsen H.S., Morcos S.K., Erley C.M., et al. Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 43 (2008) 170-178
21. Kuhn M.J., Chen N., Sahani D.V., et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol 191 (2008) 151-157
22. Carraro M., Matalan F., Antonione P., et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 8 (1998) 144-147
23. Nguyen S.A., Suranyi P., Ravenel J.G., et al. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology 248 (2008) 97-105
24. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560